Alliança Saúde e Participações S.A (AALR3) Fair Value & Analysis
Healthcare · BR · Market cap R$460M
Fair value as of: Jul 14, 2026
From 8 valuation models · updated today
Fair value updated Jul 14, 2026 — revised from R$13.75 to R$6.46 (−53.0%) since Jun 24, 2026. Share price −3.0% over the past month.
Price vs Fair Value (12 months)
12‑month range R$2.56 – R$6.76 · fair‑value band R$3.47 – R$9.45 · the R$3.20 price screens below the R$6.46 fair value. As of Jul 14, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Alliança Saúde e Participações S.A (AALR3) currently trades at R$3.20, while our model-based Fair Value estimate is R$6.46 — implying the stock looks roughly 101.9% undervalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Alliança Saúde e Participações S.A generated revenue of R$1.2B at a net margin of -6.5%. Revenue grew 3.3% year over year. It earns a return on equity of -6.2%. Net debt stands at R$836M. Fundamentals as of Jul 14, 2026
Our scenario range runs from R$3.47 (bear case) to R$9.45 (bull case); at R$3.20, the current price sits below that range. The share trades about 53% below its 52-week high and 36% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside — at 102%, AALR3 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 14, 2026. TTM = trailing twelve months.
About the company
Alliança Saúde e Participações S.A. provides diagnostic imaging and medicine services in Brazil. The company offers diagnostic imaging, clinical analysis, nuclear medicine, genetic testing, and vaccination services, as well as corporate, remote, and in-person solutions for hospitals and diagnostic centers in the private and public sectors. It provides clinical analysis services, such as blood count, cholesterol, triglycerides, urinalysis 1, stool test, detection of sexually transmitted diseases, and anatomical pathology; and diagnostic imaging services, such as magnetic resonance, computed tomography, ultrasound, x-rays, bone densitometry, mammography, scintigraphy, and PET-CT (positron emission tomography " computed tomography). It also offers graphic methods examinations, including electrocardiogram, cardiotocography, Holter, ergometric tests, and cardiopulmonary tests. Alliança Saúde e Participações S.A. was formerly known as Centro de Imagem Diagnósticos S.A. and changed its …
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Alliança Saúde e Participações S.A reported revenue of R$1.2B in FY2024 versus R$929M in FY2020, a compound +7.0%/yr. Reported net income was −R$129M in FY2024.
Is AALR3 fairly valued? → Check now
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 14, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $472.80 | $190.31 | -60% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $545.73 | $255.77 | -53% |
| Lonza Group LZAGY | $63.74 | $25.98 | -59% |
| Agilent Technologies, Inc A | $126.49 | $63.09 | -50% |
| Waters Corporation WAT | $358.25 | $106.31 | -70% |
| Integrated Diagnostics Holdings IDHC | $0.0056 | $0.0100 | +78% |
| IQVIA Holdings IQV | $167.81 | $133.89 | -20% |
| Natera, Inc NTRA | $228.80 | $24.55 | -89% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Alliança Saúde e Participações S.A (AALR3) undervalued?
What is the fair value of AALR3?
What is the quality score of AALR3?
What is the revenue of Alliança Saúde e Participações S.A (AALR3)?
What is the net profit margin of AALR3?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Alliança Saúde e Participações S.A analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.